EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

LRP8‐mediated selenocysteine uptake is a targetable vulnerability in MYCN‐amplified neuroblastoma

Hamed Alborzinia iD, Zhiyi Chen iD, Umut Yildiz iD, Florencio Porto Freitas iD, Felix C E Vogel iD, Julianna Patricia Varga, Jasmin Batani, Christoph Bartenhagen, Werner Schmitz iD, Gabriele Büchel, Bernhard Michalke iD, Jashuo Zheng iD und 21 weitere

EMBO Molecular Medicine · 07.08.2023 · 15 (8)

DOI: 10.15252/emmm.202318014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift EMBO Molecular Medicine, online erschienen am 12.07.2023. Verfasst von Hamed Alborzinia und 32 weiteren Autor:innen. Beteiligte Einrichtung: Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM GmbH), Heidelberg, Germany. Hauptthemen laut MEDLINE: Ferroptosis, Neuroblastoma. Die Arbeit wurde bisher 94-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Marie Curie, Alexander von Humboldt‐Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ferroptosis has emerged as an attractive strategy in cancer therapy. Understanding the operational networks regulating ferroptosis may unravel vulnerabilities that could be harnessed for therapeutic benefit. Using CRISPR‐activation screens in ferroptosis hypersensitive cells, we identify the selenoprotein P (SELENOP) receptor, LRP8, as a key determinant protecting MYCN ‐amplified neuroblastoma cells from ferroptosis. Genetic deletion of LRP8 leads to ferroptosis as a result of an insufficient supply of selenocysteine, which is required for the translation of the antiferroptotic selenoprotein GPX4. This dependency is caused by low expression of alternative selenium uptake pathways such as system Xc − . The identification of LRP8 as a specific vulnerability of MYCN ‐amplified neuroblastoma cells was confirmed in constitutive and inducible LRP8 knockout orthotopic xenografts. These findings disclose a yet‐unaccounted mechanism of selective ferroptosis induction that might be explored as a therapeutic strategy for high‐risk neuroblastoma and potentially other MYCN ‐amplified entities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisNeuroblastomaHumansCell Line, TumorN-Myc Proto-Oncogene ProteinSelenocysteineAnimalsLDL-Receptor Related Proteins

Stichwörter der Autor:innen

ferroptosisneuroblastomaselenocysteineselenoproteinsynthetic lethality

Substanzen

N-Myc Proto-Oncogene ProteinSelenocysteinelow density lipoprotein receptor-related protein 8LDL-Receptor Related ProteinsMYCN protein, human

Autor:innen und Institutionen

  • Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM GmbH), Heidelberg, Germany.
  • Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Rudolf Virchow Zentrum (RVZ), Center for Integrative and Translational Bioimaging, University of Würzburg, Würzburg, Germany.
  • European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany.
  • Division of Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • European Molecular Biology Organization, Heidelberg, Germany.

ORCID-Profile: Hamed Alborzinia, Zhiyi Chen, Umut Yildiz, Florencio Porto Freitas, Felix C E Vogel, Werner Schmitz, Bernhard Michalke, Jashuo Zheng, Elisa Espinet, Lisa Schlicker, Thamara N Xavier da Silva, Martin Eilers, Marcus Conrad, Marietta Fabiano, Ulrich Schweizer, Matthias Fischer, Andreas Trumpp, José Pedro Friedmann Angeli

Förderung

  • European Research Council
  • Marie Curie
  • Alexander von Humboldt‐Stiftung
  • Austrian Academy of Science
  • Bundesministerium für Bildung und Forschung
  • Deutsche Forschungsgemeinschaft
  • Deutsche Krebshilfe
  • Deutschen Konsortium für Translationale Krebsforschung

Zitieren

APA

Alborzinia, H., Chen, Z., Yildiz, U., Freitas, F. P., Vogel, F. C. E., Varga, J. P., Batani, J., Bartenhagen, C., Schmitz, W., Büchel, G., Michalke, B., Zheng, J., Meierjohann, S., Girardi, E., Espinet, E., Flórez, A. F., Dos Santos, A. F., Aroua, N., Cheytan, T., …, & Friedmann Angeli, J. P. (2023). LRP8‐mediated selenocysteine uptake is a targetable vulnerability in MYCN‐amplified neuroblastoma. EMBO Molecular Medicine, 15(8). https://doi.org/10.15252/emmm.202318014

Vancouver

Alborzinia H, Chen Z, Yildiz U, Freitas FP, Vogel FCE, Varga JP, et al. LRP8‐mediated selenocysteine uptake is a targetable vulnerability in MYCN‐amplified neuroblastoma. EMBO Molecular Medicine. 2023;15(8). doi:10.15252/emmm.202318014

BibTeX
@article{Alborzinia2023,
  author = {Alborzinia, Hamed and Chen, Zhiyi and Yildiz, Umut and Freitas, Florencio Porto and Vogel, Felix C E and Varga, Julianna Patricia and Batani, Jasmin and Bartenhagen, Christoph and Schmitz, Werner and Büchel, Gabriele and Michalke, Bernhard and Zheng, Jashuo and Meierjohann, Svenja and Girardi, Enrico and Espinet, Elisa and Flórez, Andrés F and Dos Santos, Ancely Ferreira and Aroua, Nesrine and Cheytan, Tasneem and Haenlin, Julie and Schlicker, Lisa and Xavier da Silva, Thamara N and Przybylla, Adriana and Zeisberger, Petra and Superti-Furga, Giulio and Eilers, Martin and Conrad, Marcus and Fabiano, Marietta and Schweizer, Ulrich and Fischer, Matthias and Schulze, Almut and Trumpp, Andreas and Friedmann Angeli, José Pedro},
  title = {LRP8‐mediated selenocysteine uptake is a targetable vulnerability in MYCN‐amplified neuroblastoma},
  journal = {EMBO Molecular Medicine},
  year = {2023},
  volume = {15},
  number = {8},
  doi = {10.15252/emmm.202318014}
}
Kostenlos starten →